Sugi Predict

Sugi Predict / Compounds / SCHEMBL435768

SCHEMBL435768

SCHEMBL435768

CCOc1ccc(C#N)cc1Cl

nearest known ligand 0.56

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ TRPV4 Q9HBA0 1/20 0.56
▸ PDE5A O76074 2/20 0.54
▸ AR P10275 2/20 0.54
▸ MRGPRX4 Q96LA9 5/20 0.50
▸ SLC6A4 P31645 2/20 0.48
▸ KCNH2 Q12809 2/20 0.48
▸ SLC6A3 Q01959 1/20 0.48
▸ RORC P51449 1/20 0.46
▸ MAPT P10636 1/20 0.46
▸ RAB9A P51151 1/20 0.46
▸ ATM Q13315 1/20 0.46
▸ L3MBTL1 Q9Y468 1/20 0.46
▸ ICMT O60725 1/20 0.46
▸ HTR2A P28223 1/20 0.43
▸ DRD4 P21917 1/20 0.43
▸ S1PR1 P21453 1/20 0.42
▸ FFAR1 O14842 1/20 0.41
▸ PTGDR2 Q9Y5Y4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23588252 0.86 CSNK2A1 (0.55) TRPV4PDE5AARMRGPRX4SLC6A4
SCHEMBL4179847 0.86 AR (0.68) TRPV4PDE5AARMRGPRX4SLC6A4
SCHEMBL4170196 0.85 AR (0.58) TRPV4PDE5AARMRGPRX4SLC6A4
SCHEMBL3747216 0.85 GLA (0.52) PDE5AARMRGPRX4SLC6A4KCNH2
SCHEMBL3738059 0.84 MAPT (0.47) TRPV4PDE5AARMRGPRX4SLC6A4
SCHEMBL1964745 0.83 MRGPRX4 (0.49) ARMRGPRX4SLC6A4KCNH2SLC6A3
SCHEMBL1402437 0.83 TRPV4 (0.61) TRPV4PDE5AARMAPTDRD4
SCHEMBL3739646 0.82 AR (0.48) TRPV4PDE5AARMRGPRX4SLC6A4
SCHEMBL3747473 0.82 HPGD (0.50) ARMRGPRX4SLC6A4KCNH2SLC6A3
SCHEMBL2702726 0.82 RORC (0.50) TRPV4PDE5ARORCMAPTRAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12275723-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2025-04-15 — — US disclosed
US-20240400546-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-12-05 — — US disclosed
US-20240300938-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-09-12 — — US disclosed
US-11970486-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-04-30 — — US disclosed
US-20240124435-A1 COMPOUNDS AND USES THEREOF JANSSEN PHARMACEUTICA NV (BE) 2024-04-18 — — US disclosed
CN-117777121-A Compounds and uses thereof 詹森药业有限公司 2024-03-29 — — CN disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 — — US disclosed
US-11873298-B2 Compounds and uses thereof JANSSEN PHARMACEUTICA NV (BE) 2024-01-16 — — US disclosed
CN-110099898-B Compounds and uses thereof 优曼尼蒂治疗公司 2023-07-25 — — CN disclosed
EP-3700934-A1 COMPOUNDS AND USES THEREOF Yumanity Therapeutics, Inc. (US) 2020-09-02 — — EP disclosed
WO-2018081167-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2018-05-03 — — WO disclosed
WO-2018081167-A1 COMPOUNDS AND USES THEREOF YUMANITY THERAPEUTICS (US) 2018-05-03 — — WO disclosed
US-9206173-B2 Heterocyclic compounds for the treatment of stress-related conditions OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-12-08 — — US disclosed
US-9206173-B2 Heterocyclic compounds for the treatment of stress-related conditions OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2015-12-08 — — US disclosed
US-9072758-B2 Cyclic amide derivative MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2015-07-07 — — US disclosed
US-20140057871-A1 CYCLIC AMIDE DERIVATIVE MOCHIDA PHARMACEUTICAL CO., LTD. (JP) 2014-02-27 — — US disclosed
EP-2435046-B1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS OTSUKA PHARMA CO LTD (JP) 2013-09-04 — — EP disclosed
US-20120065189-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-03-15 — — US disclosed
US-20120065189-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-03-15 — — US disclosed
WO-2010137738-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2010-12-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240124435-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 TRPV4 464/4885PDE5A 347/4885AR 4802/4885
US-20240300938-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 TRPV4 464/4885PDE5A 347/4885AR 4802/4885
US-20140057871-A1 CYCLIC AMIDE DERIVATIVE GPR119, NR0B1, NR4A1 TRPV4 867/4885PDE5A 2058/4885AR 164/4885
US-11873298-B2 Compounds and uses thereof NLN, ACHE, CLN6 TRPV4 464/4885PDE5A 347/4885AR 4802/4885
US-20240400546-A1 COMPOUNDS AND USES THEREOF NLN, ACHE, CLN6 TRPV4 464/4885PDE5A 347/4885AR 4802/4885
US-12275723-B2 Compounds and uses thereof NLN, ACHE, CLN6 TRPV4 464/4885PDE5A 347/4885AR 4802/4885
US-20120065189-A1 HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OF STRESS-RELATED CONDITIONS NR3C1, NR3C2, CRH TRPV4 2085/4885PDE5A 2426/4885AR 1673/4885
US-11970486-B2 Compounds and uses thereof NLN, ACHE, CLN6 TRPV4 464/4885PDE5A 347/4885AR 4802/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.